Physician profile
Derek Q Schroder
NPI 1326189663
$345.46
in general payments reported to CMS, 2019-2025
15 companies · $57.09 in 2025
The $57.09 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.16 · 2023: $161 · 2024: $78.03 · 2025: $57.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $113.32 | 2023-2025 | Freestyle Libre 3, Octrode |
| Pfizer INC. | $35.90 | 2019 | |
| Astellas Pharma US INC | $35.89 | 2023-2024 | Veozah |
| Abbvie INC. | $32.66 | 2025 | |
| Halozyme INC | $21.65 | 2023 | |
| Novo Nordisk INC | $19.69 | 2023 | Wegovy |
| Sumitomo Pharma America, INC. | $19.50 | 2024 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $19.36 | 2023 | Opsumit |
| Idorsia Pharmaceuticals US INC | $17.23 | 2023 | Quviviq |
| Lilly USA, LLC | $17.00 | 2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $13.26 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Schroder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.